Welcome to LookChem.com Sign In|Join Free
  • or
C24H31N3O7S2 is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1424941-94-5

Post Buying Request

1424941-94-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1424941-94-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1424941-94-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,4,9,4 and 1 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1424941-94:
(9*1)+(8*4)+(7*2)+(6*4)+(5*9)+(4*4)+(3*1)+(2*9)+(1*4)=165
165 % 10 = 5
So 1424941-94-5 is a valid CAS Registry Number.

1424941-94-5Downstream Products

1424941-94-5Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE

-

, (2015/05/13)

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be also used for the treatment of Huntington's disease, Alzheimer's disease, Multiple Sclerosis, Lateral Sclerosis, Neural Motor disorders.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE

-

, (2013/03/26)

The disclosures herein provide compounds of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral administration, transdermal administration, transmucosal, syrups, topical, extended release, sustained release, or injection. Such compositions may be used to treatment of Parkinson's disease or neurodegenerative or metabolic conditions or its associated complications.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1424941-94-5